Tilbake til søkeresultatene

PES2020-Prosj.etabl.støtte H2020

A choice of medication in treatment of solid cancers based on screening of patient’s own live cancer cells.

Tildelt: kr 49 999

Prosjektnummer:

304199

Prosjektperiode:

2019 - 2020

Midlene er mottatt fra:

Organisasjon:

Last year 17 Mn people was diagnosed with cancer. The number is steadily increasing and the forecast next year is 20 million new cancer incidence. There are more than 100 different cancers. More than 80% of all cancers are caused by solid tumors that grow as a mass of cells in a particular organ, tissue or gland. Over half of all cancers are made up of just four cancers: bowel, breast, lung, and prostate cancers. The rest are less common and rare cancer. Several of these rare cancers have a huge unmet medical need for better treatment. Seald is a biotech company developing an innovative personalised approach for treating solid cancers. Our working model Bile Duct Cancer is amongst the most aggressive and deadliest form of all cancers. On standard cell poision treatment the mean overall survival is only 11,5 months and the five-years survival less than 5%. Bile Duct Cancer afflicts three per cent of people with cancer in the digestive system. Even though categorised as rare it is a major gastrointestinal cancer due to its global prevalence. The incidence is increasing worldwide of unknown reasons. In addition, the worlds fifth common cancer, CUP (cancer of unknown primary/origin), is estimated to comprise more than 20% patients with bile duct cancer. Today cancer treatment is based on the cancer diagnose and the regulatory approved cancer drug. Cancer drug approval is based on a statistical beneficial effect on the diagnostic group. This implies that many of the patients do not have beneficial effect but only experience the side effects of the treatment. This approach causes reduced quality of life for the non-responding patients and leads to unnecessary use of societies health expenditures. Utilising a whole new approach, Seald aspires to find the right treatment for the individual patient based on a methodology combining molecular biomarkers, DNA sequencing, ex-vivo drug sensitivity analysis and xenograft models.

Budsjettformål:

PES2020-Prosj.etabl.støtte H2020